
-
Swiatek cruises, Osaka battles through in Montreal
-
Meta beats expectations sending share price soaring
-
Gaza civil defence says 30 killed in food queue by Israeli fire
-
Microsoft quarterly profits soar on AI and cloud growth
-
Airbus first-half profit climbs 85% to $1.7 bn
-
TikTok launches crowd-sourced debunking tool in US
-
'Ours forever': would-be Israeli settlers march on Gaza
-
Trump punishes Brazil with tariffs, sanctions over trial of ally Bolsonaro
-
US sprinter Kerley out of US trials
-
Ukraine will fix anti-graft law, minister tells AFP ahead of crucial vote
-
Tata Motors to buy Italy's Iveco for $4.4 bn
-
From skies over Gaza, Jordanian crew drops lifeline to civilians
-
US Fed holds firm against Trump pressure as divisions emerge
-
Michael Jackson's dirty sock sells for over $8,000 in France
-
Turkish city calls for help after heat tops 50C
-
Renault names Provost CEO after De Meo exit
-
Le Court makes history for Africa at women's Tour de France
-
Canada central bank holds rate steady citing US tariff 'threats'
-
Henry puts New Zealand in control of 1st Test against Zimbabwe
-
Stocks edge higher, dollar gains before tech earnings, Fed decision
-
Palestine Action wins bid to challenge terror ban in London court
-
EU urged to act on forests' faltering absorption of carbon
-
India secures return of ancient Buddhist gems
-
Stokes braced for 'emotional' tribute to late England batsman Thorpe
-
France's Luc Besson resurrects new 'romantic' Dracula
-
Trump hits India with 25% tariff and 'penalty' over Russia ties
-
Chinese sub discovers deepest-ever creatures 10 km undersea
-
Kingscote revels in being the 'villain' of Sussex Stakes shock
-
English cricket chiefs confirm sale of six Hundred franchises
-
Wirtz opens Liverpool account in friendly win in Japan
-
Marchand shatters record as US, Australia win more world gold
-
Thousands honour Ozzy Osbourne at UK hometown funeral procession
-
WHO chief says continuous medical aid into Gaza 'critical'
-
London court rules oligarch liable in $1.9 bn Ukraine loan scheme
-
England's Stokes out of India series decider with shoulder injury
-
Stocks diverge, dollar gains before tech earnings, Fed decision
-
India's Gill says Oval groundsman caused 'unnecessary' row
-
Physicists still divided about quantum world, 100 years on
-
Russia relieved as tsunami spares far east from major damage
-
'Can't believe it': Marchand shatters long-standing world record
-
French govt prepares new law to return colonial-era art
-
London court rules oligarch liable over $1.9 bn Ukraine loan scheme
-
Olympic biathlon champion confirmed dead after Pakistan mountaineering accident
-
German biathlete confirmed dead after accident on Pakistan mountain
-
Marchand smashes long-standing 200m medley world record
-
US economy returns to growth in second quarter on tariff turbulence
-
'All gone': Beijing villagers left with nothing after deadly floods
-
Aston Martin pares outlook as US tariffs weigh
-
Adidas says may hike US prices after tariff cost warning
-
GSK reports improved outlook despite US drug tariffs
RBGPF | -4.75% | 74.03 | $ | |
RYCEF | -2.14% | 13.1 | $ | |
CMSC | -0.04% | 22.6 | $ | |
NGG | -0.47% | 70.19 | $ | |
AZN | 3.41% | 76.59 | $ | |
GSK | 3.34% | 38.97 | $ | |
VOD | -0.45% | 11.06 | $ | |
BTI | 0.73% | 53.16 | $ | |
RIO | -4.67% | 59.49 | $ | |
RELX | -0.27% | 51.78 | $ | |
SCU | 0% | 12.72 | $ | |
BCC | -1.47% | 84.89 | $ | |
SCS | -1.74% | 10.33 | $ | |
BP | -2.2% | 32.25 | $ | |
JRI | 0.38% | 13.11 | $ | |
CMSD | -0.26% | 23.06 | $ | |
BCE | -0.55% | 23.53 | $ |

Novartis first half net profits up 29 percent
Swiss pharmaceuticals giant Novartis posted Thursday a 29 percent increase in first-half net income, at $7.6 billion -- and unveiled its new chief financial officer.
The Basel-based firm's net sales increased 12 percent to nearly $27.3 billion between January and June, it said in a statement.
Generic competition reduced its sales by two percent.
In the first half of 2025, sales of Entresto -- its flagship drug to treat chronic heart failure -- reached $4.6 billion, up 22 percent. Generic versions are expected to hit the market in the second half of the year.
Novartis chief executive Vas Narasimhan also pointed to the strong performance of other treatments such as Kisqali, for breast cancer, and Pluvicto, for prostate cancer.
The group also announced a change in its financial leadership due to take place next year.
Mukul Mehta, the head of business planning and analysis in digital finance and tax, will become the new chief financial officer in March.
He will succeed Harry Kirsch, who has held the position since 2013. Kirsch is retiring after 22 years with the company.
R.Braegger--VB